|
RETINAL DYSTROPHY WITH OR WITHOUT EXTRAOCULAR ANOMALIES
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Isolated and Syndromic Retinal Dystrophy Caused by Biallelic Mutations in RCBTB1, a Gene Implicated in Ubiquitination.
|
27486781 |
2016 |
|
RETINAL DYSTROPHY WITH OR WITHOUT EXTRAOCULAR ANOMALIES
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Isolated and Syndromic Retinal Dystrophy Caused by Biallelic Mutations in RCBTB1, a Gene Implicated in Ubiquitination.
|
27486781 |
2016 |
|
RETINAL DYSTROPHY WITH OR WITHOUT EXTRAOCULAR ANOMALIES
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Isolated and Syndromic Retinal Dystrophy Caused by Biallelic Mutations in RCBTB1, a Gene Implicated in Ubiquitination.
|
27486781 |
2016 |
|
RETINAL DYSTROPHY WITH OR WITHOUT EXTRAOCULAR ANOMALIES
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
RETINAL DYSTROPHY WITH OR WITHOUT EXTRAOCULAR ANOMALIES
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Exudative retinopathy
|
0.410 |
Biomarker
|
disease |
BEFREE |
Haploinsufficiency of RCBTB1 is associated with Coats disease and familial exudative vitreoretinopathy.
|
26908610 |
2016 |
|
Exudative retinopathy
|
0.410 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Isolated and Syndromic Retinal Dystrophy Caused by Biallelic Mutations in RCBTB1, a Gene Implicated in Ubiquitination.
|
27486781 |
2016 |
|
Familial Exudative Vitreoretinopathy
|
0.410 |
Biomarker
|
disease |
BEFREE |
Haploinsufficiency of RCBTB1 is associated with Coats disease and familial exudative vitreoretinopathy.
|
26908610 |
2016 |
|
Familial Exudative Vitreoretinopathy
|
0.410 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Isolated and Syndromic Retinal Dystrophy Caused by Biallelic Mutations in RCBTB1, a Gene Implicated in Ubiquitination.
|
27486781 |
2016 |
|
Exudative retinopathy
|
0.410 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
|
Familial Exudative Vitreoretinopathy
|
0.410 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
|
Schizophrenia
|
0.330 |
Biomarker
|
disease |
BEFREE |
To evaluate if glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce antipsychotic-associated body weight gain in patients with schizophrenia, when compared to controls.
|
30187620 |
2019 |
|
Schizophrenia
|
0.330 |
Biomarker
|
disease |
BEFREE |
The non-significant results of this first clinical trial exploring non-metabolic effects of a long-acting GLP-1RA in patients with schizophrenia could reflect a general problem of translating cognitive-enhancing effects of GLP-1RAs from animals to humans or be explained by factors specifically related to schizophrenia spectrum patients with obesity such as antipsychotic treatment.
|
28260235 |
2017 |
|
Schizophrenia
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
A diagnosis of schizophrenia is a significant predictor for increased GLP, SETDB1 mRNA expression and H3K9me2 levels in both postmortem brain and lymphocyte samples.
|
23815974 |
2013 |
|
Schizophrenia
|
0.330 |
Biomarker
|
disease |
PSYGENET |
A diagnosis of schizophrenia is a significant predictor for increased GLP, SETDB1 mRNA expression and H3K9me2 levels in both postmortem brain and lymphocyte samples.
|
23815974 |
2013 |
|
Reticular Dystrophy Of Retinal Pigment Epithelium
|
0.300 |
GermlineCausalMutation
|
disease |
ORPHANET |
Isolated and Syndromic Retinal Dystrophy Caused by Biallelic Mutations in RCBTB1, a Gene Implicated in Ubiquitination.
|
27486781 |
2016 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Despite the early positioning of GLP-1RA in T2D treatment algorithms, GLP-1RA have been prescribed in patients with progressively more advanced disease stage and especially in the presence of cardiovascular disease.
|
31673896 |
2020 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Whereas glucose control using classical glucose-lowering agents (except perhaps metformin) largely fails to reduce cardiovascular disease (CVD), two new pharmacological classes, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter type 2 inhibitors (SGLT2is), have proven their ability to reduce major cardiovascular events in patients with established CVD.
|
31108136 |
2020 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1RAs and SGLT2i are now advocated as second-line agents in European and US guidelines for management of both hyperglycaemia and for primary prevention of cardiovascular disease in people with T2DM.
|
31551292 |
2020 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Lately, GLP-1RAs have spiked the interest of researchers and clinicians due to their beneficial effects on CVD.
|
31825468 |
2020 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
Modulation of platelet function by diabetes agents in addition to their hypoglycemic effects would contribute to cardiovascular protection Newly introduced antidiabetic drugs of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors may have anti-platelet effects, and in the case of SGLT2i and GLP-1RA may contribute to their proven cardiovascular benefit that has been shown clinically.
|
31612835 |
2020 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1RAs are associated with a reduction in cardiovascular morbidity and mortality in high-risk patients with diabetes.
|
31595657 |
2020 |
|
Diabetes
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are two classes of antidiabetic agents used in the management of diabetes based on incretin hormones.
|
31837333 |
2020 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Modulation of platelet function by diabetes agents in addition to their hypoglycemic effects would contribute to cardiovascular protection Newly introduced antidiabetic drugs of sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors may have anti-platelet effects, and in the case of SGLT2i and GLP-1RA may contribute to their proven cardiovascular benefit that has been shown clinically.
|
31612835 |
2020 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
GLP-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase 4 inhibitors (DPP-4i) are two classes of antidiabetic agents used in the management of diabetes based on incretin hormones.
|
31837333 |
2020 |